Chen, et al. (2018) [25]  In vivo on a rabbit model  Intravaginal implant designed to release an HCQ concentration above 4.34 µg/mL but below 21.7 µg/mL6 days  After 6 days, there was seen an improvement of mucosal epithelial integrity, a reduction in submucosal immune cell recruitment, a decrease of gene expression and T cell activation marker protein, and a minimization of key pro-inflammatory mediators activation.  Not reported.  No clinical study has been designed to test the effectiveness of HCQ in preventing HIV infection